Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies.1 Icotrokinra also showed ...
From more than 30 target action dates in the last three months of the year, BioSpace has narrowed the list to six regulatory ...
From 1 October to 31 October, six of our favourite restaurants across Sydney, Melbourne and Brisbane are dusting off the ...
Some welcome the renewed focus and pledges of research money for autism. Others are outraged by what they consider the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback